You are here

Developing Therapeutics That Target RAD51 to Treat Leukemia and Lymphoma

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA183197-01
Agency Tracking Number: R41CA183197
Amount: $213,466.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA13-089
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
HINSDALE, IL 60521-2829
United States
DUNS: 78512533
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (207) 288-6820
Business Contact
Phone: (630) 789-9931
Research Institution
BAR HARBOR, ME 04609-1500
United States

 () -
 Domestic nonprofit research organization

DESCRIPTION (provided by applicant): Genomic instability is a hallmark of cancer, yet is underdeveloped as a therapeutic target area The central goal of this program is to develop new cancer therapeutics that target genomic instability as a hallmark of cancer cells, bringing new, cancer-cell selective treatments to the clinical oncology market. Two key challenges in current cancer therapy are minimizing the side effects associated with chemotherapy; and preventing tumor cell evolution by acquired mutations that drive cancer progression and therapy resistance. Therapies that target genomic instability mechanisms have the potential to meet these critical clinical challenges. In recent years, the B-cell specific DNA mutase/recombinase Activation Induced Cytidine Deaminase (AID) has been implicated as a driver of oncogenic genomic instability. While its expression is normally restricted to activated, germinal center B-cells, AID is also overexpressed in a range of human neoplasms, especially B-cell lymphom

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government